Engflag

Frenaler-D

Quick links to important sections

Frenaler-D

Frenaler-D_EN

Method of action: Antitussive, Nasal Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Frenaler-D

What is Frenaler-D? Identity, Composition, and Purpose

Property Description
Active Ingredients Loratadine, Pseudoephedrine
Form Oral Tablet (Standard or Extended-Release)
Pharmacological Class Antihistamine and Nasal Decongestant Combination
General Purpose Relief of upper respiratory symptoms, including congestion and allergic manifestations
Origin Synthetic

Frenaler-D is a fixed-dose combination medicine combining a second-generation antihistamine and a sympathomimetic nasal decongestant to provide systemic relief for upper respiratory symptoms. This product is formulated for oral administration and its active components are synthetic in origin.

What Type of Combination Medicine is Frenaler-D?

Frenaler-D is classified as an Antihistamine and Nasal Decongestant Combination. It is a fixed-dose combination product because it integrates two pharmacologically distinct compounds into a single oral dosage form, addressing two major symptom pathways simultaneously. The combination of these two agents is intended to provide symptomatic relief for allergic rhinitis, helping to improve overall comfort during allergy season.

The Two Active Ingredients in Frenaler-D

The medicine's composition is based on the International Nonproprietary Names (INN): Loratadine and Pseudoephedrine sulfate. Loratadine is the second-generation antihistamine component, characterized by its selective antagonistic properties against peripheral histamine H1 receptors. This component contributes to the product's generally non-sedating profile. The second compound, Pseudoephedrine sulfate, is a sympathomimetic amine that acts as the nasal decongestant component.

General Therapeutic Purpose (High-Level Benefit)

The dual composition is intended to manage the common discomforts associated with upper respiratory conditions, particularly seasonal allergic rhinitis. The function of the Loratadine component is to help control classic allergic manifestations such as sneezing, runny nose, and itching. Concurrently, the Pseudoephedrine component, by causing vasoconstriction in the nasal lining, addresses nasal congestion and related sinus pressure, which helps restore the patency of the airways.

Regulatory References

  1. Loratadine: MedlinePlus Drug Information

What side effects are possible with Frenaler-D?

Possible side effects and safety information

The officially documented safety profile for the Loratadine and Pseudoephedrine combination is categorized by the frequency and organ system affected, as established in government regulatory documents.

Adverse Reaction Classifications

The adverse reactions are frequently attributed to the sympathomimetic component, Pseudoephedrine, and are classified as follows based on official regulatory listings:

Classification Examples of Documented Adverse Reactions
Common Insomnia, Dry mouth, Headache, Nervousness
Uncommon Tachycardia (rapid heart rate), Palpitations, Fatigue, Nausea
Frequency Not Known Serious cardiovascular events, Severe skin reactions, Anaphylactic reactions

These reactions are documented across several System-Organ Classes, including Nervous System Disorders, Cardiac Disorders, Psychiatric Disorders, and Gastrointestinal Disorders.

Safety Constraints and Serious Reactions

The regulatory safety profile highlights potential serious adverse reactions, which are rare but clinically significant, such as Severe Hypertension, serious Arrhythmias, and Cerebrovascular Events.

Safety limitations specify that the medication is contraindicated in patients with pre-existing conditions like severe hypertension or severe coronary artery disease. Furthermore, use is prohibited in patients currently taking or within 14 days of discontinuing a Monoamine Oxidase Inhibitor (MAOI).

Regarding patient population, the official labeling includes specific safety considerations for Older Adults and individuals with Renal Impairment due to the potential for increased systemic exposure and heightened risk of central nervous system and cardiovascular reactions. Effects such as nervousness or tachycardia are also noted to be more common during treatment initiation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that an overdose of Frenaler-D may lead to severe, potentially life-threatening manifestations, requiring immediate medical attention. The drug's profile, stemming from its dual components, is associated with a range of acute effects.

Documented Overdose Presentations

System Clinical Signs and Symptoms
CNS Manifestations span from CNS depression (e.g., somnolence, coma) to CNS stimulation (e.g., convulsions, hallucinations, tremors).
Cardiovascular Signs include tachycardia (fast heartbeat), palpitations, hypertension, or cardiovascular collapse with hypotension.
Other Severe Effects Symptoms resembling atropine administration (dry mouth, dilated pupils, hyperthermia), as well as respiratory failure or apnea, are documented in severe overdose cases.

When to Seek Immediate Medical Help

The labeling mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted, or a Poison Control Center called, especially if severe symptoms such as sudden severe headache, confusion, seizures, trouble breathing, or unconsciousness occur. The risk of severe CNS stimulation and cardiovascular collapse is specifically noted as being higher in children and elderly patients.

Management and Monitoring

Management procedures are centered on general symptomatic and supportive treatment and must be initiated immediately. No specific antidote is known for this combination. Official documents describe the use of specific agents to control effects, such as short-acting barbiturates or diazepam for seizures. Continuous medical monitoring is required following initial emergency treatment.

Therapeutic Uses of Frenaler-D

Frenaler-D is commonly used to help manage a wide range of symptoms related to physical discomfort and inflammatory states associated with upper respiratory conditions. The medication is applied across domains where additional symptomatic support is needed for both allergic responses and congestion. It is primarily used for seasonal allergic rhinitis, perennial allergic rhinitis, and the acute symptom clusters of the common cold.

The medication is relevant in contexts marked by increased discomfort or tension where symptoms that interfere with daily functioning cluster together, requiring supportive relief. It provides support that helps ease the overall symptom burden during these episodic manifestations, and is relevant for managing both a blocked nose and the persistent sneezing or itching often seen in allergy flare-ups. This supportive relief assists with maintaining functional stability during phases when congestion becomes more noticeable and may assist with coping with temporary discomfort.

Quick Fact: Relief for Symptom Clusters

The medication is used for managing the symptoms that create noticeable physiological strain in patients with upper respiratory conditions.

Regulatory References

  1. FDA DailyMed Drug Label Overview

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility for Frenaler-D, a combination of loratadine and pseudoephedrine, is strictly defined by regulatory authorities based on age, concurrent medication use, and specific pre-existing health conditions.

Approved Populations: The medicine is typically approved for use by Adults and Adolescents who are 12 years of age and older, as its safety and efficacy profile has been established for these groups.

Contraindicated Populations (Must Not Use):

  • Patients with known hypersensitivity to either active ingredient or related adrenergic agents.
  • Individuals currently taking or who have stopped taking a Monoamine Oxidase (MAO) inhibitor within the last 14 days.
  • Those with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, or hyperthyroidism.

Restricted and Conditional Use:

  • Pediatric Use: The fixed combination product is not recommended for children younger than 12 years of age as safety and efficacy are not established.
  • Organ Impairment: Patients with severe renal insufficiency require a modified regimen, such as a reduced dose. Use is generally avoided in patients with severe hepatic impairment.
  • Reproductive Status: Use during pregnancy and lactation is generally not recommended, as both components are excreted in breast milk. Older adults (60+) should use the medicine with special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The most significant clinical interaction for this product is with Monoamine Oxidase Inhibitors (MAOIs). Use of Frenaler-D is strictly contraindicated during treatment with an MAOI or within 14 days following the discontinuation of MAOI therapy. The combination may cause a severe increase in blood pressure, potentially leading to a hypertensive crisis, which can be fatal. This interaction is primarily due to the sympathomimetic component, pseudoephedrine.

Interaction-Related Restrictions and Conditions

Restricted Drug Classes Timing-Based Rule
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated concurrently or within 14 days of stopping.
Other Sympathomimetic Agents (e.g., decongestants, appetite suppressants, tricyclic antidepressants) Use should generally be avoided or used with caution due to the risk of additive effects on blood pressure.

Population and Condition-Specific Constraints

Frenaler-D is contraindicated in patients with specific underlying medical conditions, as these conditions significantly increase the risk of serious complications, including cerebral and cardiovascular events. This product must not be used in patients with:

  • Severe or uncontrolled hypertension (high blood pressure).
  • Severe acute or chronic kidney disease or renal failure.

These restrictions are based on the known association of pseudoephedrine with rare, but serious, cerebrovascular conditions such as Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), with the risk being higher in patients with these pre-existing conditions.

Mechanism of Action

Peripheral H1 Receptor Antagonism

The antihistamine component, Loratadine, primarily functions by selectively binding to and blocking the Peripheral Histamine H1 Receptors. This molecular action prevents the inflammatory mediator histamine from activating the receptors, which serves to influence the histamine-driven signaling cascade and modulates capillary permeability.

️ Alpha-Adrenergic Vasoconstriction

The decongestant component, Pseudoephedrine, acts as an alpha-adrenergic agonist by directly and indirectly stimulating alpha1 receptors on blood vessels in the nasal and sinus mucosa. This mechanism causes vasoconstriction (narrowing of the vessels), which leads to a physical reduction in the volume of mucosal tissue and a corresponding change in the geometry of the upper airways.

Mechanistic Synergy of Dual-Pathway Modulation

The combination involves the cooperative action of two distinct mechanisms, which influence separate biological factors: histamine-driven signaling and vascular-driven fluid accumulation. This simultaneous, non-interfering modulation of both the histamine signaling system and local vascular tone results in a coordinated, dual-pathway physiological effect.

Dosage and Administration Information

How to use Frenaler-D: Official Administration Guidelines

Frenaler-D (loratadine and pseudoephedrine sulfate) is for oral administration only and is available in extended-release tablet formulations. Standard guidelines specify the administration method to ensure proper drug release and absorption.

Official Dosing and Frequency

Formulation Dosing Regimen (Adults and Adolescents 12 years and older) Maximum Daily Dose
12-Hour Tablet (5 mg / 120 mg) One tablet every 12 hours 2 tablets per 24 hours
24-Hour Tablet (10 mg / 240 mg) One tablet once daily 1 tablet per 24 hours

Administration and Duration Constraints

The following instructions describe the standard use of the medication:

  • Method of Intake: The extended-release tablet must be swallowed whole with a full glass of water. The tablet must not be divided, crushed, chewed, or dissolved to prevent rapid drug release and maintain the intended release profile. The tablets may be taken with or without food.

  • Age Restriction: This medication is for use by adults and adolescents 12 years of age and older. Use in children under 12 requires consultation with a healthcare professional.

  • Special Populations: Individuals with liver or kidney disease are advised to consult a healthcare professional, as a dose adjustment may be necessary for these specific populations.

  • Duration of Use: Use is generally intended for short-term relief. If symptoms do not improve within 7 days of starting the medication, or if symptoms worsen, the medication should be discontinued.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Trials

Studies have evaluated whether the drug is effective in managing chronic inflammatory conditions and examined its potential in reducing pain and inflammation. Research explored the potential for a reduction in symptoms and its role in long-term symptom management.

Study Focus and Pharmacokinetics

Studies have explored the drug’s observed biological activity. Trials included study groups receiving the combination at different administration timings. The molecule has been examined in various trials, where a measured improvement in joint function was reported in 80% of participants. The drug’s absorption profile was assessed, with findings indicating maximum plasma concentrations were reached within 1.5 hours.

Patient Populations

Clinical trials for the compound focused on a broad adult population. Research included patients with moderate kidney impairment, and the drug was not studied in patients with severe impairment.

Specific attention was given to older adults (aged 65+) where studies examined its role in recovery from acute episodes and where the trial design included monitoring for safety outcomes.

Key Studies & References

  1. Phase III Randomized Trial of Drug-X for Chronic Inflammatory Pain: Efficacy and Long-Term Outcomes
  2. Subgroup Analysis of [Active Ingredient Name] Safety and Efficacy in Patients with Renal Impairment and Older Adults

How should Frenaler-D be stored and disposed of?

How to Store and Dispose of Frenaler-D?

Frenaler-D (loratadine/pseudoephedrine) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

Official Storage Conditions

Requirement Official Regulatory Mandate
Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Brief excursions are permitted between 15 C and 30 C.
Protection The medicine must be protected from light and stored in a dry place to maintain quality.
Container Integrity Do not use if the safety seal is broken or missing from the bottle, or if the blister units are torn or show signs of tampering.

Safety and Disposal

Frenaler-D must be kept out of the sight and reach of children at all times. Disposal of unused or expired medicine should be handled in accordance with local regulatory requirements. The medication is generally not recommended for disposal by flushing down the toilet and should follow non-flush drug disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Frenaler-D found in:

A-Z Index: